Low lymphocyte monocyte ratio after neoadjuvant therapy predicts poor survival after pancreatectomy in patients with borderline resectable pancreatic cancer

The impact of systemic immune inflammatory markers to predict survival in patients receiving neoadjuvant therapy for borderline resectable pancreatic cancer has not been sufficiently investigated. This study aims to evaluate whether systemic immune inflammatory markers after neoadjuvant therapy foll...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Surgery 2019-06, Vol.165 (6), p.1151-1160
Hauptverfasser:	Kawai, Manabu, Hirono, Seiko, Okada, Ken-ichi, Miyazawa, Motoki, Shimizu, Atsushi, Kitahata, Yuji, Kobayashi, Ryohei, Ueno, Masaki, Hayami, Shinya, Tanioka, Kensuke, Yamaue, Hiroki
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Aged, 80 and over Antineoplastic Agents Antineoplastic Combined Chemotherapy Protocols - therapeutic use Biomarkers, Tumor - blood Carcinoma, Pancreatic Ductal - immunology Carcinoma, Pancreatic Ductal - mortality Carcinoma, Pancreatic Ductal - pathology Carcinoma, Pancreatic Ductal - therapy Chemoradiotherapy, Adjuvant Databases, Factual Female Follow-Up Studies Humans Lymphocyte Count Lymphocytes - metabolism Male Middle Aged Monocytes - metabolism Neoadjuvant Therapy Pancreatectomy - mortality Pancreatic Neoplasms - immunology Pancreatic Neoplasms - mortality Pancreatic Neoplasms - pathology Pancreatic Neoplasms - therapy Prognosis Retrospective Studies Survival Analysis
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!